Aptorum Group Ltd Class A (APM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aptorum Group Ltd Class A stock (APM) is currently trading at $1.16. Aptorum Group Ltd Class A PS ratio (Price-to-Sales) is 23.35. Analyst consensus price target for APM is $80.00. WallStSmart rates APM as Sell.
- APM PE ratio analysis and historical PE chart
- APM PS ratio (Price-to-Sales) history and trend
- APM intrinsic value — DCF, Graham Number, EPV models
- APM stock price prediction 2025 2026 2027 2028 2029 2030
- APM fair value vs current price
- APM insider transactions and insider buying
- Is APM undervalued or overvalued?
- Aptorum Group Ltd Class A financial analysis — revenue, earnings, cash flow
- APM Piotroski F-Score and Altman Z-Score
- APM analyst price target and Smart Rating
Aptorum Group Ltd Class A
📊 No data available
Try selecting a different time range
Smart Analysis
Aptorum Group Ltd Class A (APM) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Aptorum Group Ltd Class A (APM) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Aptorum Group Ltd Class A (APM) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very expensive at 23.4x annual revenue
Very low institutional interest at 2.43%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Aptorum Group Ltd Class A (APM) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.39) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (23.35) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -14.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -14.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
APM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
APM's Price-to-Sales ratio of 23.35x trades at a deep discount to its historical average of 59.65x (54th percentile). The current valuation is 96% below its historical high of 523x set in May 2019, and 952% above its historical low of 2.22x in Nov 2022. Over the past 12 months, the PS ratio has expanded from ~13.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Aptorum Group Ltd Class A (APM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Aptorum Group Ltd Class A operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.15 indicates a conservative balance sheet with 3M in cash.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -484,283, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Aptorum Group Ltd Class A.
Bottom Line
Aptorum Group Ltd Class A offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Aptorum Group Ltd Class A(APM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Aptorum Group Limited, a pharmaceutical company, is dedicated to the discovery, development and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. The company is headquartered in London, the United Kingdom.